Observations placeholder

Humira

Identifier

017717

Type of Spiritual Experience

Hallucination

Number of hallucinations: 196

Background

A description of the experience

Adalimumab

Adalimumab, trade names Humira ("human monoclonal antibody in rheumatoid arthritis") and Exemptia.

Is marketed as HUMIRA   - "Human Monoclonal Antibody in Rheumatoid Arthritis".  It was the third TNF inhibitor, after infliximab and etanercept, to be approved in the United States. Like infliximab and etanercept, adalimumab binds to TNFα, preventing it from activating TNF receptors; adalimumab was constructed from a fully human monoclonal antibody, while infliximab is a mouse-human chimeric antibody and etanercept is a TNF receptor-IgG fusion protein.

It is used in the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, moderate to severe chronic psoriasis and juvenile idiopathic arthritis.

 On Dec, 26, 2016   358,739 people reported to have side effects when taking Humira.  Among them, 165 people (0.05%) have Hallucination

On Dec, 28, 2016 358,739 people reported to have side effects when taking Humira.  Among them, 31 people (0.01%) have Hallucination, Auditory

Time on Humira when people have Hallucination  :

  < 1 month 1 - 6 months 6 - 12 months 1 - 2 years 2 - 5 years 5 - 10 years 10+ years
Hallucination 39.29% 39.29% 0.00% 10.71% 10.71% 0.00% 0.00%

Gender of people who have Hallucination when taking Humira  :

  Female Male
Hallucination 82.93% 17.07%

Age of people who have Hallucination when taking Humira  :

  0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Hallucination 0.00% 0.00% 1.52% 19.70% 7.58% 3.03% 10.61% 57.58%

 

On Dec, 21, 2016 358,739 people reported to have side effects when taking Humira.  Among them, 2,790 people (0.78%) have Death

 

The source of the experience

eHealthme

Concepts, symbols and science items

Concepts

Symbols

Science Items

TNFs

Activities and commonsteps

Commonsteps

References